Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOCO-CHF: Levosimendan in advanced chronic heart failure
NCT03576677Phase 4Unknown
- Start
- Aug 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of levosimendan in heart failure (HF). Primary endpoint: Change in Cardiac Output / Pulmonary Capillary Wedge Pressure at submaximal exercise at Day 5. Status: unknown.
02
Drugs
levosimendan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03576677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576677.